ORNBV Orion Oyj Class B

ORION CORPORATION: ACQUISITION OF OWN SHARES 14.09.2022

ORION CORPORATION: ACQUISITION OF OWN SHARES 14.09.2022

Orion Corporation NOTIFICATION

 

14.09.2022 at 18:30

 

ORION CORPORATION: ACQUISITION OF OWN SHARES 14.09.2022



 

Date14.09.2022 
Exchange transaction Buy 
Share classORNBV 
Amount11,000  
Average price/share45.2128EUR
Highest price/share45.5000EUR
Lowest price/share44.9900EUR
Total price497,340.80 EUR
   

 

The shares held by Orion Corporation on 14.09.2022:

 ORNBV 670,677 

 

 

On behalf of Orion Corporation

 

 

Skandinaviska Enskilda Banken AB (Publ)

 



 

Antti Salakka        Janne Tiihonen

 

 

For more information, please contact:

Olli Huotari, SVP, Corporate Functions, Orion Corporation

tel. 4

 

Attachment



EN
14/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal...

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal  ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST         Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal  Orion to discontinue development of ODM-105 for insomnia.ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized. Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with insomnia. Accor...

 PRESS RELEASE

Orionin vaiheen 2 tutkimus ODM-105:llä unettomuuden hoidossa ei saavut...

Orionin vaiheen 2 tutkimus ODM-105:llä unettomuuden hoidossa ei saavuttanut ensisijaista tavoitettaan ORION OYJ        LEHDISTÖTIEDOTE        30.9.2025 KLO 13.00         Orionin vaiheen 2 tutkimus ODM-105:llä unettomuuden hoidossa ei saavuttanut ensisijaista tavoitettaan Orion lopettaa ODM-105:n kehityksen unettomuuden hoitoon.ODM-105 (tasipimidiini) oli hyvin siedetty. Yksityiskohtaisten tulosten, mukaan lukien turvallisuusdata, valmistuminen ja arviointi on vielä kesken. Orion Oyj:n lääkekandidaatti ODM-105 (tasipimidiini) ei saavuttanut ensisijaista tavoitettaan unettomuuspotilaiden h...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS30 September 2025 at 9.00 EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 26 Septembe...

 PRESS RELEASE

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoit...

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) ORION OYJ        PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE        30.9.2025 KLO 9.00         Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n mukaisen ilmoituksen, jonka mukaan BlackRock, Inc.:n ja sen rahastojen suoraan, välillisesti ja rahoitusinstrumenttien kautta omistamien Orionin osakkeiden osuus on 26.9.2025 alittanut viisi (5) prosenttia Orion Oyj:n kaikista osakkeista. BlackRoc...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS26 September 2025 at 16.30 EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 25 Septemb...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch